0.10
0.10 (-30.32%)
As of Oct 13, 2023
Bellerophon Therapeutics, Inc. [BLPH]
Source:
Company Overview
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company focused on developing innovative products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Our focus is the continued development of our nitric oxide therapy for patients with or at risk of pulmonary hypertension, or PH, using our proprietary pulsatile nitric oxide delivery platform, INOpulse.
| Country | United States |
| Headquarters | warren, new jersey |
| Phone Number | 908-574-4770 |
| Industry | manufacturing |
| CEO | Peter Fernandes |
| Website | www.bellerophon.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-2.2 |
| Net Income | $-1.9 |
| Net Cash | $-2.8 |
Profit Ratios
| Gross Margin | |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -29.8% |
| Profit as % of Stockholder Equity | -51.6% |
Management Effectiveness
| Return on Equity | -51.6% |
| Return on Assets | -38.6% |
| Turnover Ratio | 0% |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $5 |
| Total Liabilities | $1.3 |
| Operating Cash Flow | $-8 |
| Investing Cash Flow | $0.1 |
| Financing Cash Flow | $5 |
